• Policy
• Zerbaxa passed evaluation committee after 4 yrs of challenge
• by Lee, Tak-Sun Jun 3, 2022 06:36am

• Policy
• Lioresal was newly listed
• by Kim, Jung-Ju Jun 2, 2022 05:59am

• Opinion
• [Reporter’s View] Differing indication and reimb standards
• by Eo, Yun-Ho Jun 2, 2022 05:58am

• Policy
• New guidelines for Lagevrio & Paxlovid have been released
• by Kim, Jung-Ju Jun 2, 2022 05:58am

• Policy
• The GMP reinforcement bill passed the plenary session
• by Lee, Jeong-Hwan Jun 2, 2022 05:58am

• Company
• Commercialization of ADC Enhertu is imminent in Korea
• by Eo, Yun-Ho Jun 2, 2022 05:58am

• Policy
• 22nd new homegrown drug Acelex adds side effect after PMS
• by Lee, Hye-Kyung May 31, 2022 06:06am

• Company
• Evusheld to be introduced in Korea
• by Eo, Yun-Ho May 31, 2022 06:06am

• Company
• Handok to “speed up global P2T for its BTC candidate"
• by Kim, Jin-Gu May 31, 2022 06:05am

• Company
• PalPal's sales are 5.1 billion won
• by Kim, Jin-Gu May 31, 2022 06:05am